Cineol: Effects in Respiratory Diseases

Cineol, chemically 1,8 cineol or eucalyptol, is a cyclic monoterpene oxide and the main constituent of essential oils from many plants, particularly eucalyptus. Cineol is also found in varying concentrations in bay leaf, sage, mugwort, cardamom, and tea tree. In Germany, highly pure 1,8 cineol is approved as a herbal medicinal product (Soledum, Aspecton, Bronchoforton, and generics) for the treatment of acute and chronic respiratory diseases.

Compared to classical mucolytics such as acetylcysteine or ambroxol, cineol pursues a slightly different approach. It acts as a secretolytic, secretomotor, and anti-inflammatory agent. Studies also suggest a moderate bronchodilatory component and a reduction in inflammatory mediators, making it an interesting option for chronic bronchitis, asthma as an adjunct, and sinusitis.

Mechanism of Action

Cineol exerts its effects through multiple mechanisms following oral intake. First, it promotes liquefaction and clearance of bronchial mucus by stimulating the activity of cilia in the respiratory epithelium while simultaneously reducing the viscosity of secretions. Second, cineol inhibits the synthesis of pro inflammatory cytokines and mediators in cell cultures and animal models, partly through modulation of the NF kappa B signaling pathway. Third, it appears to exert moderate spasmolytic effects on smooth bronchial muscle.

Clinically, these effects manifest in a reduction in cough frequency, mucus volume, and airway obstruction. Cineol is rapidly absorbed following oral intake, with maximum effect occurring after approximately two hours. The half life averages six hours, with metabolism occurring predominantly hepatically via CYP3A4 and CYP2A6 to hydroxy metabolites, which are renally excreted.

Of pharmacodynamic interest is the fact that cineol may enhance endogenous glucocorticoid effects in respiratory tissues. These observations stem primarily from in vitro studies and should not be overinterpreted, yet they form a basis for adjunctive use in asthma and COPD adjuvant therapy.

Uses

• Acute bronchitis with thick sputum and cough, short term symptomatic therapy
• Chronic bronchitis and exacerbated chronic obstructive pulmonary disease as adjunctive therapy
• Acute and chronic rhinosinusitis, often also as adjuvant therapy following endoscopic sinus surgery
• Adjuvant in bronchial asthma in stable phase, supplementary to established stepwise base therapy
• Prevention of deterioration in chronic respiratory diseases, examined in individual clinical studies

Cineol is not a substitute for guideline compliant therapy in asthma or COPD. In acute exacerbations, severe pneumonias, or when antibiotic therapy is necessary, classical measures apply.

Dosage and Administration

Adults and adolescents from 12 years: 200 mg three times daily for acute symptoms, if needed up to four times daily in the first few days. Maintenance dose 200 mg twice daily. Maximum dose depending on manufacturer 1200 mg per day.

Children from 4 years: 100 mg two to three times daily, depending on preparation and indication, always in age appropriate formulation.

Administration: gastric acid resistant capsules should be swallowed whole approximately 30 minutes before meals with plenty of cool liquid. Do not take with warm beverages, as these can damage the gastric acid resistant coating.

Duration of therapy: for acute bronchitis and sinusitis usually seven to fourteen days. With chronic bronchitis and COPD, longer term use over weeks to several months is possible, always under medical supervision.

Renal insufficiency: generally no dose adjustment required. Hepatic insufficiency: with severe hepatic dysfunction, cautious use is advised due to altered metabolism.

Side Effects

Common: dry mouth, belching with eucalyptus like taste, mild gastrointestinal complaints such as nausea or heartburn.

Occasional: allergic skin reactions with itching or rash, breathing difficulties with hypersensitivity to essential oils, headaches.

Rare: bronchospasm in very sensitive individuals with asthma, especially with inhalative use in high concentrations.

Note: Concentrated essential oils are not suitable for direct application to mucous membranes or in infants. On the skin of small children, eucalyptus oils in high concentration can lead to seizures.

Drug Interactions

• CYP3A4 substrates (for example some calcium antagonists, statins, immunosuppressants): cineol may mildly induce CYP3A4, which could be relevant with long term high dose use. Clinically, such interactions are however limited in evidence.
• Other essential oils such as peppermint oil, thyme oil: additive mucous membrane effects and potentially increased bronchospasm tendency in very sensitive patients.
• Antitussives such as codeine and dextromethorphan: from a pharmacological standpoint it makes sense to separate them, because cineol facilitates expectoration while strong antitussives suppress cough reflex.
• Bronchodilators such as salbutamol or formoterol: no relevant pharmacokinetic interactions, clinically often a sensible combination.

Special Precautions

Pregnancy and lactation: data limited. Routine use is not recommended, in individual cases therapy can be undertaken following individual risk assessment with a physician.

Infants and small children under 4 years: use not recommended due to risk of seizures and airway narrowing, especially with direct inhalation or skin application of eucalyptus oil.

Narrow angle glaucoma: with pre existing glaucoma, caution with eye proximate application of essential oils, oral cineol administration is largely independent of this.

Asthma: patients with hyperreactive airways should coordinate use in the initial dosing phase with their physician, because in rare cases bronchospasms can be triggered.

Allergies: with known hypersensitivity to eucalyptus, sage or other Lamiaceae plants, caution is advised.

Lifestyle: drink adequate fluids, inhalation with warm steam and nasal irrigation with physiological saline solution complement the effect.

You Might Also Be Interested In

• Acetylcysteine, secretolytic amino acid derivative
• Ambroxol, classical mucolytic for bronchitis
• Bromhexin, secretolytic agent for productive cough
• Dextromethorphan, cough suppressant for dry irritant cough
• Salbutamol, short acting beta 2 agonist for acute bronchial obstruction

Frequently Asked Questions

Sources

• Gelbe Liste, Cineol Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines for Acute Bronchitis and Rhinosinusitis
• EMA, Herbal Medicinal Products Committee, Eucalyptus Monographs